clonidine has been researched along with Brain Ischemia in 11 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to investigate the protective effects of the alpha-2 adrenergic receptor (α2-AR) agonist, clonidine, on the cerebral ischemia-reperfusion (I/R) injury and elaborate the underlying mechanisms." | 8.12 | Clonidine ameliorates cerebral ischemia-reperfusion injury by up-regulating the GluN3 subunits of NMDA receptor. ( Chen, J; Chen, Y; He, Z; Li, ZC; Yang, DD; Zhang, J; Zhao, B, 2022) |
| "Clonidine, a classical α-2 adrenergic agonists, has been shown to antagonize brain damage caused by hypoxia, cerebral ischemia and excitotoxicity and reduce cerebral infarction volume in recent studies." | 7.88 | Clonidine preconditioning improved cerebral ischemia-induced learning and memory deficits in rats via ERK1/2-CREB/ NF-κB-NR2B pathway. ( Chen, Z; He, Z; Li, Y; Li, Z; Wang, Y; Yan, L; Yu, L; Yu, M; Zeng, X; Zha, Y; Zhang, W; Zhao, B, 2018) |
| "The present study was undertaken to investigate the effects of the alpha2 adrenergic agonist, clonidine, on the near complete cerebral ischemia (NCFI) evoked release of glutamate and aspartate from normo- and hyperglycemic rodent brain tissue using microdialysis tissue techniques." | 7.73 | The effect of clonidine on cell survival, glutamate, and aspartate release in normo- and hyperglycemic rats after near complete forebrain ischemia. ( Jellish, WS; Kindel, G; Murdoch, J; White, FA; Zhang, X, 2005) |
| "This study aimed to investigate the protective effects of the alpha-2 adrenergic receptor (α2-AR) agonist, clonidine, on the cerebral ischemia-reperfusion (I/R) injury and elaborate the underlying mechanisms." | 4.12 | Clonidine ameliorates cerebral ischemia-reperfusion injury by up-regulating the GluN3 subunits of NMDA receptor. ( Chen, J; Chen, Y; He, Z; Li, ZC; Yang, DD; Zhang, J; Zhao, B, 2022) |
| "Clonidine, a classical α-2 adrenergic agonists, has been shown to antagonize brain damage caused by hypoxia, cerebral ischemia and excitotoxicity and reduce cerebral infarction volume in recent studies." | 3.88 | Clonidine preconditioning improved cerebral ischemia-induced learning and memory deficits in rats via ERK1/2-CREB/ NF-κB-NR2B pathway. ( Chen, Z; He, Z; Li, Y; Li, Z; Wang, Y; Yan, L; Yu, L; Yu, M; Zeng, X; Zha, Y; Zhang, W; Zhao, B, 2018) |
| " Experiment 1 characterized the effects of 10 min forebrain ischemia on corticosterone (CORT) secretion following ischemia and in response to spatial memory assessment in the Barnes maze, as well as the impact of pre-ischemia treatment with the glucocorticoid inhibitor metyrapone (175 mg/kg; s." | 3.77 | Changes in HPA reactivity and noradrenergic functions regulate spatial memory impairments at delayed time intervals following cerebral ischemia. ( Milot, MR; Plamondon, H, 2011) |
| "The present study was undertaken to investigate the effects of the alpha2 adrenergic agonist, clonidine, on the near complete cerebral ischemia (NCFI) evoked release of glutamate and aspartate from normo- and hyperglycemic rodent brain tissue using microdialysis tissue techniques." | 3.73 | The effect of clonidine on cell survival, glutamate, and aspartate release in normo- and hyperglycemic rats after near complete forebrain ischemia. ( Jellish, WS; Kindel, G; Murdoch, J; White, FA; Zhang, X, 2005) |
| "Sub-acute brain ischemia is a risk factor for the development of vascular dementia (VaD)." | 1.40 | Pharmacological modulation of I(1)-imidazoline and α2-adrenoceptors in sub acute brain ischemia induced vascular dementia. ( Gupta, S; Sharma, B, 2014) |
| "Selective role of spasticity was estimated in clinical pattern of motor disorders in groups of the patients with different disorders of muscular tonus with the same degree of paresis." | 1.30 | [Disorders of muscle tonus and their treatment with sirdalud in patients in the early recovery period of ischemic stroke]. ( Beliakov, VV; Burd, GS; Gekht, AB; Iaish, F; Selikhova, MV, 1998) |
| "Clonidine-treated rats received fentanyl/N2O and 10 micrograms/kg of intravenous clonidine 10 min before ischemia, which was produced by right carotid ligation combined with hemorrhagic hypotension to 35 mm Hg for 30 min." | 1.28 | Clonidine decreases plasma catecholamines and improves outcome from incomplete ischemia in the rat. ( Albrecht, RF; Baughman, VL; Cheng, MA; Hoffman, WE; Thomas, C, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Monjas, L | 1 |
| Arce, MP | 1 |
| León, R | 1 |
| Egea, J | 1 |
| Pérez, C | 1 |
| Villarroya, M | 1 |
| López, MG | 1 |
| Gil, C | 1 |
| Conde, S | 1 |
| Rodríguez-Franco, MI | 1 |
| Chen, J | 1 |
| Zhang, J | 1 |
| Yang, DD | 1 |
| Li, ZC | 1 |
| Zhao, B | 2 |
| Chen, Y | 1 |
| He, Z | 2 |
| Li, Y | 1 |
| Yu, M | 1 |
| Wang, Y | 1 |
| Zha, Y | 1 |
| Li, Z | 1 |
| Yu, L | 1 |
| Yan, L | 1 |
| Chen, Z | 1 |
| Zhang, W | 1 |
| Zeng, X | 1 |
| Gupta, S | 1 |
| Sharma, B | 1 |
| Milot, MR | 1 |
| Plamondon, H | 1 |
| Treggiari, MM | 1 |
| Romand, JA | 1 |
| Martin, JB | 1 |
| Reverdin, A | 1 |
| Rüfenacht, DA | 1 |
| de Tribolet, N | 1 |
| Richter, F | 1 |
| Mikulik, O | 1 |
| Ebersberger, A | 1 |
| Schaible, HG | 1 |
| Jellish, WS | 1 |
| Murdoch, J | 1 |
| Kindel, G | 1 |
| Zhang, X | 1 |
| White, FA | 1 |
| Gekht, AB | 1 |
| Burd, GS | 1 |
| Selikhova, MV | 1 |
| Iaish, F | 1 |
| Beliakov, VV | 1 |
| Reis, DJ | 1 |
| Regunathan, S | 1 |
| Meeley, MP | 1 |
| Hoffman, WE | 1 |
| Cheng, MA | 1 |
| Thomas, C | 1 |
| Baughman, VL | 1 |
| Albrecht, RF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cervical Sympathetic Block to Increase Cerebral Blood Flow in Patients With Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage[NCT05230134] | 10 participants (Anticipated) | Interventional | 2023-07-27 | Enrolling by invitation | |||
| Stellate Ganglion Block for the Treatment of COVID-19-Induced Olfactory Dysfunction: A Prospective Pilot Study[NCT05445921] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2022-09-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Participants will be asked to complete the ODOR, which is a patient-reported outcome measure assessing physical problems, functional limitations, and emotional consequences of olfactory dysfunction.~The ODOR has a minimum score of 0 and a maximum score of 112 with higher scores indicating a greater degree of impairment and limitation. The minimal clinically important difference is a change of 15 points." (NCT05445921)
Timeframe: baseline, 5-10 days post SGB #1, and 1 month
| Intervention | score on a scale (Median) | ||
|---|---|---|---|
| ODOR at Baseline | ODOR at 1 Week | ODOR at 1 Month | |
| Stellate Ganglion Block | 62 | 57 | 50.5 |
"Participants will complete the 40-item scratch and sniff UPSIT and mean change will be assessed.~The UPSIT has a minimum score of 0 and maximum score of 40 with lower scores indicating a greater degree of impairment. An UPSIT score of >33 for men and >34 for women is considered normosmic, and the minimal clinically important difference is a change of 4 points." (NCT05445921)
Timeframe: baseline, 5-10 days, and 1 month
| Intervention | units on a scale (Median) | ||
|---|---|---|---|
| UPSIT at Baseline | UPSIT at 1 Week | UPSIT at 1 Month | |
| Stellate Ganglion Block | 16.5 | 21 | 22.5 |
Participants will be asked about their change in olfactory dysfunction on a 7-point Likert scale from much better to much worse. (NCT05445921)
Timeframe: 5-10 days post SGB #1 and 1 month
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI-I for Smell Loss at 1 Week71922197 | CGI-I for Smell Loss at 1 Month71922197 | CGI-I for Smell Distortion at 1 Week71922197 | CGI-I for Smell Distortion at 1 Month71922197 | CGI-I for Taste Loss at 1 Week71922197 | CGI-I for Taste Loss at 1 Month71922197 | CGI-I for Taste Distortion at 1 Week71922197 | CGI-I for Taste Distortion at 1 Month71922197 | |||||||||||||||||||||||||
| About the Same | Slightly Better | Much Better | Moderately Better | |||||||||||||||||||||||||||||
| Stellate Ganglion Block | 8 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 10 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 9 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 11 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 6 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 1 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 15 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 4 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 0 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 14 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 3 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 2 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 13 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 12 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 5 | |||||||||||||||||||||||||||||||
Participants will be asked about the severity of their olfactory dysfunction (and gustatory dysfunction) on a 5-point Likert scale from no smell loss to severe smell loss. (NCT05445921)
Timeframe: baseline, 5-10 days, and 1 month
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI-S for Smell Loss at Baseline71922197 | CGI-S for Smell Loss at 1 Week71922197 | CGI-S for Smell Loss at 1 Month71922197 | CGI-S for Smell Distortion at Baseline71922197 | CGI-S for Smell Distortion at 1 Week71922197 | CGI-S for Smell Distortion at 1 Month71922197 | CGI-S for Taste Loss at Baseline71922197 | CGI-S for Taste Loss at 1 Week71922197 | CGI-S for Taste Loss at 1 Month71922197 | CGI-S for Taste Distortion at Baseline71922197 | CGI-S for Taste Distortion at 1 Week71922197 | CGI-S for Taste Distortion at 1 Month71922197 | |||||||||||||||||||||||||||||||||||||||||||||||||
| No Problem | Very Mild Problem | Mild Problem | Moderate Problem | Severe Problem | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 review available for clonidine and Brain Ischemia
| Article | Year |
|---|---|
Imidazole receptors and clonidine-displacing substance in relationship to control of blood pressure, neuroprotection, and adrenomedullary secretion.
Topics: Adrenal Medulla; Blood Pressure; Brain Chemistry; Brain Ischemia; Clonidine; Humans; Imidazoline Rec | 1992 |
1 trial available for clonidine and Brain Ischemia
| Article | Year |
|---|---|
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
9 other studies available for clonidine and Brain Ischemia
| Article | Year |
|---|---|
Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Calcium Channel Blockers; Cholinesterase Inhibitors; Don | 2017 |
Clonidine ameliorates cerebral ischemia-reperfusion injury by up-regulating the GluN3 subunits of NMDA receptor.
Topics: Animals; Brain Ischemia; Clonidine; Infarction, Middle Cerebral Artery; Male; Neuroprotective Agents | 2022 |
Clonidine preconditioning improved cerebral ischemia-induced learning and memory deficits in rats via ERK1/2-CREB/ NF-κB-NR2B pathway.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brain Ischemia; Clonidine; Cyclic AMP Response Elemen | 2018 |
Pharmacological modulation of I(1)-imidazoline and α2-adrenoceptors in sub acute brain ischemia induced vascular dementia.
Topics: Acetylcholinesterase; Adrenergic alpha-2 Receptor Agonists; Animals; Brain; Brain Ischemia; Catalase | 2014 |
Changes in HPA reactivity and noradrenergic functions regulate spatial memory impairments at delayed time intervals following cerebral ischemia.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Analysis of Variance; | 2011 |
Noradrenergic agonists and antagonists influence migration of cortical spreading depression in rat-a possible mechanism of migraine prophylaxis and prevention of postischemic neuronal damage.
Topics: Adrenergic alpha-Agonists; Adrenergic Antagonists; Adrenergic beta-Antagonists; Animals; Blood Press | 2005 |
The effect of clonidine on cell survival, glutamate, and aspartate release in normo- and hyperglycemic rats after near complete forebrain ischemia.
Topics: Adrenergic alpha-Agonists; Animals; Aspartic Acid; Blood Glucose; Blood Pressure; Brain Chemistry; B | 2005 |
[Disorders of muscle tonus and their treatment with sirdalud in patients in the early recovery period of ischemic stroke].
Topics: Adult; Aged; Brain Ischemia; Clonidine; Female; H-Reflex; Humans; Male; Middle Aged; Muscle Relaxant | 1998 |
Clonidine decreases plasma catecholamines and improves outcome from incomplete ischemia in the rat.
Topics: Animals; Blood Glucose; Brain Ischemia; Catecholamines; Clonidine; Hemodynamics; Injections, Intrave | 1991 |